Clinical trials: Monocytes
Ulcerative Colitis
CESA 5.10 Investigation to Compare the Efficacy and Safety of the Adacolumn® Apheresis Device in Patients With Active Ulcerative Colitis
The purpose of this study is to compare the safety and efficacy of 5 Adacolumn® treatments over 5 weeks to 10 treatments (two Adacolumn® apheresis treatments during the first 2 weeks, followed by 6 weeks with one Adacolumn®…
- Trial name
- NCT00366925
- Testing
- Adacolumn®
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- Otsuka Frankfurt Research Institute GmbH
Colorectal Cancer
Peripheral Blood Monocytes as Predictive Marker for Colorectal Cancer Diagnosis: A Comparative Study of a Stool Based Versus Blood Based Screening Test
In this prospective study, the main goal is to evaluate the strength of Monomark -a monocyte-based transcriptomic test combined to a mathematical model- in patients with a positive FIT test.
- Trial name
- MonoFIT+ (NCT03462992)
- Testing
- MonoMark
- Where
- Belgium
- Volunteers
- 250 people
- Sponsor
- DNAlytics
Leukemia
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354276
- Testing
- cytarabine, laromustine
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- Vion Pharmaceuticals
Gram Positive Infection
Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males
Results from previous studies have been inconclusive and the effect of linezolid on cytokines remains unclear. This study is designed to evaluate the effect of linezolid on the functionality of white blood cells (neutrophils and…
- Trial name
- NCT01544673
- Testing
- linezolid
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acute Myeloid Leukemia, Leukemia
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status.
- Conditions
- Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome, AML
- Trial name
- NCT00462761
- Testing
- AC220
- Where
- 5 sites in United States, Georgia
- Volunteers
- 76 people
- Sponsor
- Daiichi Sankyo
Sepsis
Clinical Trial to Evaluate MDW for Early Detection of Sepsis
This study is intended to clinically verify Monocyte Distribution Width (MDW) parameter of DxH 900 Hematology Analyzer for use in early detection and risk assessment of sepsis, severe sepsis, and septic shock in critically ill…
- Trial name
- NCT06267742
- Testing
- Complete Blood Count (CBC) with Differential
- Where
- 3 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Beckman Coulter, Inc.
Childhood Solid Tumor
Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood
This is an un-blinded Phase 1 study in which 21 patients suffering from solid advanced paediatric malignancies (14 sarcoma and 7 non-sarcoma patients) are treated with AV0113, an anti-tumour immune therapy with autologous…
- Trial name
- NCT02533895
- Testing
- AV0113 DC-CIT, Data evaluation
- Where
- 2 sites in Austria
- Volunteers
- 67 people
- Sponsor
- Activartis Biotech
Metabolic Syndrome
Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome
The purpose of this study is to examine in detail the acute and chronic effects of pitavastatin on plasma lipid transport and atheroma biomarkers in patients at elevated risk for the premature development of atherosclerosis…
- Trial name
- CAPITAIN (NCT01595828)
- Testing
- Pitavastatin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Kowa Research Europe
Sepsis, Severe Infection
Evaluation of Monocyte Volume Distribution Width (MDW) for Early Detection of Sepsis
The measurement of monocyte volume width distribution (MDW) is intended for use with adult patients presenting to the emergency department (ED), where a CBC with Differential has been ordered, as an aid in the early detection of…
- Trial name
- MDW (NCT03145428)
- Testing
- CBC-Diff Monocyte volume width distribution (MDW)
- Where
- 3 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Beckman Coulter, Inc.
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML)
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to…
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
- Trial name
- NCT06950034
- Testing
- STX-0712
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Solu Therapeutics, Inc
Chronic Inflammatory Diseases, Type 2 Diabetes Mellitus
NOX-E36 First-in-Human (FIH) Study
This is the first time NOX-E36 will be administered to man. The principal aim of this study is to obtain safety and tolerability data when NOX-E36 is administered by single intravenous (IV) and subcutaneous (SC) doses to healthy…
- Conditions
- Chronic Inflammatory Diseases, Type 2 Diabetes Mellitus, Systemic Lupus Erythematosus
- Trial name
- NCT00976729
- Testing
- NOX-E36
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- TME Pharma AG
Metastatic Cancer
In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides
The purpose of this study is to evaluate in vitro the potential of peptides, to modify, phenotypically and functionally, the monocyte-derived dendritic cells of patients with metastatic cancer.
- Trial name
- NCT02159937
- Testing
- Blood sampling by vena punction.
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Recepta Biopharma
AML With Monocytic Differentiation, CMML
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04372433
- Testing
- IO-202, IO-202 and Azacitidine, IO-202 and Azacitidine + Venetoclax
- Where
- 14 sites in United States
- Volunteers
- 67 people
- Sponsor
- Immune-Onc Therapeutics
Ulcerative Colitis
ADAPT Adacolumn Pediatric Trial in Ulcerative Colitis
Children aged up to 18 years with moderately active Ulcerative Colitis (PUCAI:35-64) will receive one weekly Adacolumn® apheresis treatment over 5 consecutive weeks, followed by up to 3 optional Adacolumn® apheresis treatments…
- Trial name
- NCT00781638
- Testing
- Adacolumn®
- Volunteers
- 24 people
- Sponsor
- Otsuka Frankfurt Research Institute GmbH
AML M4, AML M5
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
This study evaluates the safety and efficacy of novel ILT3-targeted CAR-T cell therapy for patients with relapsed or refractory acute myeloid leukemia (M4/M5).
- Trial name
- NCT04803929
- Testing
- anti-ILT3 CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Carbiogene Therapeutics Co. Ltd.
Acute Kidney Injury
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI)…
- Trial name
- NEUTRALIZE-AKI (NCT05758077)
- Testing
- Selective Cytopheretic Device, Standard of Care
- Where
- 36 sites in United States
- Volunteers
- 339 people
- Sponsor
- SeaStar Medical
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood.
- Conditions
- Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy
- Trial name
- IMAGINE (NCT05138458)
- Testing
- MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Myeloid Therapeutics
HIV Infections
The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection
To evaluate the ability of the combination of indinavir, zidovudine, and lamivudine to suppress HIV-1 infection as measured by: (1) the maintenance of HIV-1 serum viral RNA below the limit of detection of the most sensitive…
- Trial name
- NCT00002179
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 17 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
Sepsis
Adult MDW Dual Cut-Off Accuracy Study
This study will establish the clinical performance of the Monocyte Distribution Width (MDW) parameter on the DxH 900/ DxH 690T hematology analyzers to aid in the detection and risk assessment of patients in the Emergency…
- Trial name
- MDW (NCT06885528)
- Testing
- Complete Blood Count with differential
- Where
- 5 sites in United States
- Volunteers
- 524 people
- Sponsor
- Beckman Coulter, Inc.
HER2-positive
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors…
- Trial name
- NCT06254807
- Testing
- CT-0525
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Carisma Therapeutics Inc